Skip to Content

Press Releases

Press Releases

Mar 13 2020
Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update
JERUSALEM , March 13, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 and provides a corporate update.  Highlights from the Quarter and Recent Weeks Developed an Accordion Pill
Feb 25 2020
Intec Pharma to Participate at Three Investment Conferences in March
JERUSALEM , Feb. 25, 2020 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 40th Annual Health Care Conference Date: March 2-5, 2020 Company
Jan 30 2020
Intec Pharma Announces Pricing of $6.5 Million Public Offering
JERUSALEM , Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu
Jan 30 2020
Intec Pharma Announces Proposed Public Offering
JERUSALEM , Jan. 30, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares in
Jan 09 2020
Intec Pharma Issues Letter to Shareholders
JERUSALEM , Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill ® platform, in a Letter to Shareholders.
Dec 11 2019
Intec Pharma Provides Update on Novartis Feasibility and Option Agreement
JERUSALEM , Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill ® (AP) for a proprietary Novartis compound, despite
Dec 06 2019
Intec Pharma to Present at LD Micro's 12th Annual Main Event
JERUSALEM , Dec. 6, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Company management will be participating in the 12 th Annual LD Micro Main Event investor conference. 12 th  Annual LD Micro Main Event Date: December 10-12, 2019
Dec 03 2019
Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital
JERUSALEM , Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC (" Aspire Capital "), a Chicago -based institutional
Nov 13 2019
Intec Pharma to Participate in Jefferies London Healthcare Conference
JERUSALEM , Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference .  Jefferies London Healthcare Conference Date: November 20-21, 2019 Company
Nov 12 2019
Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update
JERUSALEM , Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2019 . Highlights of the third quarter 2019 and recent weeks include: Presented two posters highlighting data
Displaying 1 - 10 of 106